Payment overview · 2025
General Payments
$602.43
31 reported records · 16 companies
Healthcare provider profile · identity verified
Daniel Yanfeng Lin, MD, PHD
Allopathic & Osteopathic Physicians|Family Medicine · PHILADELPHIA, PA · NPI 1073781621
Verified facts
What the public records show
CMS Open Payments records show Daniel Yanfeng Lin, MD, PHD received $602.43 in general payments during 2025 across 31 reported records.
Sumitomo Pharma America, Inc. accounted for 18.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vemlidy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $108.64 | 18.0% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $71.59 | 11.9% | 4 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $71.38 | 11.8% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $60.61 | 10.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.50 | 7.4% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.21 | 7.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.49 | 4.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.11 | 4.0% | 1 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $23.08 | 3.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.31 | 3.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.75 | 3.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.72 | 3.3% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $18.64 | 3.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.00 | 3.0% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.53 | 2.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.87 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $602.43 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $108.64 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $76.07 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $60.61 | 3 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $43.21 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $26.00 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.49 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.11 | 1 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $22.31 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 44 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 134 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 171 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
171 | 46 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
62 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
134 | 33 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
134 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
44 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1062 | 302 |
| Amlodipine Besylate | Amlodipine Besylate | 866 | 225 |
| Simvastatin | Simvastatin | 780 | 212 |
| Losartan Potassium | Losartan Potassium | 673 | 188 |
| Metformin Hcl | Metformin Hcl | 601 | 161 |
| Tamsulosin Hcl | Tamsulosin Hcl | 591 | 168 |
| Alendronate Sodium | Alendronate Sodium | 562 | 153 |
| Donepezil Hcl | Donepezil Hcl | 532 | 96 |
| Meloxicam | Meloxicam | 496 | 240 |
| Diclofenac Sodium | Diclofenac Sodium | 476 | 213 |
| Januvia | Sitagliptin Phosphate | 475 | 98 |
| Omeprazole | Omeprazole | 436 | 135 |
| Lisinopril | Lisinopril | 411 | 104 |
| Vascepa | Icosapent Ethyl | 382 | 104 |
| Metformin Hcl Er | Metformin Hcl | 368 | 93 |
| Fluticasone Propionate | Fluticasone Propionate | 354 | 177 |
| Trazodone Hcl | Trazodone Hcl | 348 | 81 |
| Allopurinol | Allopurinol | 344 | 105 |
| Azithromycin | Azithromycin | 314 | 222 |
| Hydrochlorothiazide | Hydrochlorothiazide | 306 | 85 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 278 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 267 | 70 |
| Hydrocortisone | Hydrocortisone | 266 | 147 |
| Finasteride | Finasteride | 239 | 69 |
| Prednisone | Prednisone | 237 | 149 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 230 | 122 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 223 | 151 |
| Gabapentin | Gabapentin | 222 | 81 |
| Naproxen | Naproxen | 213 | 118 |
| Ezetimibe | Ezetimibe | 197 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 191 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 186 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 182 | 70 |
| Mirtazapine | Mirtazapine | 179 | 59 |
| Glipizide Er | Glipizide | 177 | 51 |
| Linzess | Linaclotide | 171 | 46 |
| Famotidine | Famotidine | 156 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 156 | 35 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 153 | 40 |
| Meclizine Hcl | Meclizine Hcl | 145 | 92 |
| Jardiance | Empagliflozin | 134 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 130 | 61 |
| Pioglitazone Hcl | Pioglitazone Hcl | 121 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 121 | 47 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 112 | 46 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 111 | 49 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 106 | 17 |
| Eliquis | Apixaban | 105 | 26 |
| Montelukast Sodium | Montelukast Sodium | 95 | 27 |
| Carvedilol | Carvedilol | 94 | 26 |
| Glimepiride | Glimepiride | 92 | 27 |
| Gemfibrozil | Gemfibrozil | 91 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 25 |
| Fenofibrate | Fenofibrate,micronized | 86 | 27 |
| Acarbose | Acarbose | 84 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 81 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 78 | 55 |
| Ofloxacin | Ofloxacin | 74 | 53 |
| Cephalexin | Cephalexin | 67 | 53 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 65 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 14 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 64 | 38 |
| Farxiga | Dapagliflozin Propanediol | 62 | 12 |
| Amoxicillin | Amoxicillin | 59 | 50 |
| Glipizide | Glipizide | 59 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 59 | 15 |
| Sucralfate | Sucralfate | 59 | 42 |
| Ammonium Lactate | Ammonium Lactate | 53 | 38 |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | 11 |
| Lansoprazole | Lansoprazole | 49 | 39 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 48 | 15 |
| Nitroglycerin | Nitroglycerin | 48 | 14 |
| Atenolol | Atenolol | 46 | 14 |
| Entecavir | Entecavir | 45 | suppressed |
| Colchicine | Colchicine | 44 | 19 |
| Gemtesa | Vibegron | 44 | 26 |
| Celecoxib | Celecoxib | 42 | 31 |
| Furosemide | Furosemide | 42 | 15 |
| Clobetasol Propionate | Clobetasol Propionate | 41 | 17 |
| Nifedipine Er | Nifedipine | 40 | 13 |
| Ibuprofen | Ibuprofen | 39 | 30 |
| Clarithromycin | Clarithromycin | 38 | 36 |
| Loperamide | Loperamide Hcl | 37 | 29 |
| Clonazepam | Clonazepam | 36 | suppressed |
| Restasis | Cyclosporine | 36 | 14 |
| Lovastatin | Lovastatin | 34 | suppressed |
| Tradjenta | Linagliptin | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 32 | 20 |
| Ketoconazole | Ketoconazole | 31 | 17 |
| Clonidine Hcl | Clonidine Hcl | 29 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 21 |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Procto-Med Hc | Hydrocortisone | 27 | 16 |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 24 | 13 |
| Valacyclovir | Valacyclovir Hcl | 24 | 19 |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Erythromycin | Erythromycin Base | 19 | 15 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Ciclopirox | Ciclopirox | 16 | 12 |
| Vemlidy | Tenofovir Alafenamide | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Repaglinide | Repaglinide | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 11 |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | 11 |
| Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $602.43 · 31 records | Sumitomo Pharma America, Inc. | ACCRUFER, AIRSUPRA, Cologuard Collection Kit, EVENITY, GEMTESA, JARDIANCE, Kerendia, LINZESS, MONOFERRIC, NUZYRA, Ozempic, PROLIA, PURIFIED CORTROPHIN GEL, REPATHA, VOQUEZNA, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error